QIAGEN (NYSE:QGEN) has obtained
CE marking for its newly developed QIAstat-Dx Respiratory SARS-CoV-2
Panel test to be sold as an in vitro diagnostic (“IVD”) for the
detection of SARS-CoV-2.
As the first syndromic testing solution in the
European Union, the QIAstat-Dx test kit can differentiate coronavirus
from 21 other serious respiratory infections in a single testing run of
about one hour.
The newly approved panel includes assays targeting two genes used to detect the pathogen behind the disease.
Shares are down 2% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.